CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D045888: Ganglion Cysts NIH

(Synonyms: Ganglion Cysts)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (4)


Name (Synonyms) Correlation
drug2739 Stellate Ganglion Block Wiki 1.00
drug409 Biological collection (patients co infected HIV Sras-CoV-2) Wiki 0.71
drug2300 Qualitative interviews (in 40 patients : 20 with COVID-19 and 20 without COVID-19) Wiki 0.71
drug296 Auto-questionnaires (patients co infected HIV Sras-CoV-2) Wiki 0.71

Correlated MeSH Terms (4)


Name (Synonyms) Correlation
D013577 Syndrome NIH 0.07
D055371 Acute Lung Injury NIH 0.07
D012127 Respiratory Distress Syndrome, Newborn NIH 0.07
D012128 Respiratory Distress Syndrome, Adult NIH 0.06

Correlated HPO Terms (0)


Name (Synonyms) Correlation

There are 2 clinical trials

Clinical Trials


1 Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS)

The purpose of this study is to understand if it is safe and useful to perform SGB (Stellate Ganglion Block) in patients who have severe lung injury Acute Respiratory Distress Syndrome (ARDS) due to COVID-19 infection.

NCT04402840 Acute Respiratory Distress Syndrome COVID-19 Procedure: Stellate Ganglion Block
MeSH:Ganglion Cysts Respiratory Distress Syndrome, Newborn Respiratory Distress Syndrome, Adult Acute Lung Injury Syndrome

Primary Outcomes

Description: Adverse events that can atleast unlikely be attributed to SGB

Measure: Adverse events related to SGB

Time: 3 Months

Description: All adverse events related to COVID-19

Measure: All Adverse events

Time: 3 Months

Description: Death due to any cause

Measure: Death

Time: 3 Months

Secondary Outcomes

Description: Change from baseline (descibed as last ratio prior to procedure)

Measure: PaO2/FiO2 or SpO2/FiO2(SF) ratio change from baseline

Time: 3 Months

Description: change from last imaging data obtained prior to SGB procedure

Measure: Radiographic criteria

Time: 3 Months

Measure: Incidence of cardiac arrhythmia

Time: 3 Months

Measure: Resolution of cardiac arrhythmia

Time: 3 Months

Measure: Cardiac function

Time: 3 Months

Measure: Clinical relevant Laboratory testing (d-dimer, Ferritin, Troponin T, LDH)

Time: 3 Months

2 Stellate Ganglion Blockade in COVID-19 Positive Patients

This study will establish the safety and efficacy of using stellate ganglion blocks in patients with ARDS due to COVID-19 disease.

NCT04445337 COVID 19 ARDS Procedure: Stellate Ganglion Block
MeSH:Ganglion Cysts

Primary Outcomes

Description: Adverse events related to SGB.

Measure: Evaluate the safety of a new modified stellate ganglia block (SGB) in ARDS

Time: 3 month

Secondary Outcomes

Description: All adverse events.

Measure: Evaluate the efficacy of a new modified stellate ganglia block (SGB) in ARDS

Time: 3 month


HPO Nodes